WIPO - Search International and National Patent Collections

1.WO/2026/098555USE OF ANTI-RSV ANTIBODY IN PREVENTION AND TREATMENT OF RSV

WO - 15.05.2026

Int.Class C07K 16/10 Appl.No PCT/CN2025/133017 Applicant ZHUHAI TRINOMAB PHARMACEUTICAL CO., LTD. Inventor DING, Jiyuan

Provided in the present invention are an anti-RSV antibody and the use of the anti-RSV antibody in the preparation of a drug for preventing or treating RSV infections or symptoms or diseases related thereto, wherein the RSV infections comprise subtype A and subtype B infections and upper respiratory tract RSV infections and/or lower respiratory tract RSV infections, and the symptoms or diseases related to RSV infections comprise fevers, coughs, sore throats, runny noses, and dyspnea, bronchitis or pneumonia caused by RSV infections.

2.20260124239A COMPOSITION COMPRISING BLOOD PLASMA AND IMMUNOGLOBULINS FOR USE IN THE TREATMENT OR PREVENTION OF AN INFECTIOUS DISEASE

US - 07.05.2026

Int.Class A61K 35/16 Appl.No 19118287 Applicant Onderzoeks- en Ontwikkelingsfonds Rode Kruis-Vlaanderen Inventor Hendrik Feys

The present invention relates to a composition for use in the treatment or prevention of a respiratory infectious disease in a subject, wherein said composition comprises blood plasma and immunoglobulins directed against a causative agent of said respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease; and wherein said composition is administered intranasally, and optionally orally. The present invention further relates to a nasal, naso-oropharyngeal, or oro-nasal spray device comprising such composition and a nasal, naso-oropharyngeal, or oro-nasal spray comprising blood plasma and immunoglobulins directed against a causative agent of said respiratory infectious disease, wherein said immunoglobulins are obtained from a donor subject who has developed a humoral immune response to said causative agent of said respiratory infectious disease.

3.121537507一种抗MERS的纳米抗体、纳米抗体融合蛋白及其应用

CN - 21.04.2026

Int.Class C07K 16/102 Appl.No 202610069433.5 Applicant 中国人民解放军军事科学院军事医学研究院 Inventor 迟象阳

本发明提供了一种抗MERS的纳米抗体、纳米抗体融合蛋白及其应用，属于抗体药物技术领域，所述抗MERS的纳米抗体，包括如下CDR1、CDR2和CDR3区的氨基酸序列：CDR1：GSIFSRYT；CDR2：ITSEGNT；CDR3：NAGGGGAYFYHGAS。本发明中的所述纳米抗体通过噬菌体展示技术筛选获得，具有独特的CDR分区，其抗原识别表位位于S1蛋白的RBD区域。本发明提供的抗MERS的纳米抗体融合蛋白具有高表达、高稳定性、高特异性、高亲和力、低免疫原性以及低成本规模化生产的特点，适合产业化生产，有望用于应对MERS大流行潜在危机，具有重大应用价值。

4.121889421广泛靶向冠状病毒的双特异性抗体

CN - 17.04.2026

Int.Class C07K 16/104 Appl.No 202480048498.0 Applicant 美国政府（由卫生和人类服务部的部长所代表） Inventor J·H·Y·谭

公开了双特异性抗体，包括特异性结合冠状病毒刺突蛋白（例如SARS‑CoV‑2）的双可变结构域免疫球蛋白。还公开了这些抗体用于抑制冠状病毒感染的用途。此外，还公开了使用公开的抗体检测生物样本中冠状病毒的方法。

5.121873224靶向RSV F蛋白的单克隆抗体及其检测试剂盒和应用

CN - 17.04.2026

Int.Class C07K 16/11 Appl.No 202610344474.0 Applicant 北京师范大学 Inventor 郎青云

本发明涉及靶向RSV F蛋白的单克隆抗体、其相关产品和应用。本发明的单克隆抗体（AD5）或其抗原结合片段特异性结合RSV F蛋白Site III抗原表位。本发明的抗体AD5兼具靶向高保守性表位（Site III）和具有高中和活性的特点，克服了现有上市抗体靶向高保守性表位时中和活性不高的主要缺陷。

6.121873221一种F11单克隆抗体及其用途

CN - 17.04.2026

Int.Class C07K 16/104 Appl.No 202411439416.3 Applicant 南方医科大学珠江医院 Inventor 徐伟

本发明公开了一种F11单克隆抗体及其用途，该F11单克隆抗体用于特异性结合SARS‑CoV‑2的刺突蛋白S2亚基中的6HB结构域，包含重链可变区的VHCDR1‑3和轻链可变区的VLCDR1‑3，VHCDR1、VHCDR2和VHCDR3的氨基酸序列分别如SEQ ID NO.1、SEQ ID NO.3和SEQ ID NO.5所示，VLCDR1、VLCDR2和VLCDR3的氨基酸序列分别SEQ ID NO.2、SEQ ID NO.4和SEQ ID NO.6所示。本发明F11单克隆抗体可中和SARS‑CoV‑2的病毒感染，在新冠病毒的血清学检测、制备新冠病毒感染检测的试剂及新冠病毒抗原或抗体检测的试剂中具有重要的应用价值。

7.121873223一种H5N1广谱多靶点治疗性抗体及其制备方法与应用

CN - 17.04.2026

Int.Class C07K 16/108 Appl.No 202610073423.9 Applicant 南开大学 Inventor 楼瀚涛

本发明提供一种H5N1广谱多靶点治疗性抗体及其制备方法与应用，属于生物医学技术领域，该治疗性抗体可同时识别结合H5N1血凝素蛋白的HA亚基N端、融合肽区域等四个关键表位，为人源化单克隆抗体，含特定重链和轻链序列。其对H1N1、H3N2、H5N1等多种甲型流感病毒的IC50值为0.22~9.76μg/ml，中和效力较现有抗体提高，且4℃储存24个月活性保持>90%，稳定性优异。制备方法通过重组多靶点HA抗原制备、筛选及CHO细胞表达纯化实现。本发明解决了现有抗体靶向单一、易逃逸、中和弱的问题，可用于制备预防或治疗多种甲型流感病毒感染的药物，应用前景广阔。

8.121873217一种靶向乙肝表面抗原的纳米抗体及其应用

CN - 17.04.2026

Int.Class C07K 16/082 Appl.No 202511616660.7 Applicant 重庆医科大学 Inventor 蔡雪飞

本发明公开了一种靶向乙肝表面抗原的纳米抗体及其应用。该纳米抗体具有如SEQ ID NO:1‑5所示的氨基酸序列，对HBsAg具有高亲和力。该纳米抗体不仅能有效中和乙肝病毒，还能进入细胞内部，对病毒生命周期实现“多环节、全方位”抑制，包括抑制病毒RNA转录、蛋白表达、核衣壳组装、DNA复制和颗粒分泌，并能显著下调宿主肝细胞中HNF4α、Sp1等关键转录因子。该抗体可在原核或真核系统中高效表达。其PEG化衍生物（如Nb1‑PEG40）能延长半衰期，在HBV感染小鼠模型中展现出更强的清除血清HBsAg和抑制肝脏病毒复制的效果。本发明为乙肝治疗提供了新的策略和药物候选。

9.121873222一种F1单克隆抗体及其用途

CN - 17.04.2026

Int.Class C07K 16/104 Appl.No 202411439418.2 Applicant 南方医科大学珠江医院 Inventor 徐伟

本发明公开了一种F1单克隆抗体及其用途，该F1单克隆抗体用于特异性结合SARS‑CoV‑2的刺突蛋白S2亚基中的6HB结构域，包含重链可变区的VHCDR1‑3和轻链可变区的VLCDR1‑3，VHCDR1、VHCDR2和VHCDR3的氨基酸序列分别如SEQ ID NO.1、SEQ ID NO.3和SEQ ID NO.5所示，VLCDR1、VLCDR2和VLCDR3的氨基酸序列分别SEQ ID NO.2、SEQ ID NO.4和SEQ ID NO.6所示。本发明F1单克隆抗体能够中和SARS‑CoV‑2的病毒感染，在新冠病毒的血清学检测、制备新冠病毒感染检测的试剂及新冠病毒抗原或抗体检测的试剂中具有重要的应用价值。

10.WO/2026/080293ANTI-HUMAN RSV F PROTEIN ANTIBODIES FOR USE IN TREATMENT OR PROPHYLAXIS

WO - 16.04.2026

Int.Class C07K 16/46 Appl.No PCT/US2025/049180 Applicant MERCK SHARP & DOHME LLC Inventor MAAS, Brian Matthew

The present invention relates to methods of preventing and/or treating RSV-related diseases with the methods and compositions of the invention.

1 / 503

Go to Search input	`CTRL` + `SHIFT` +
Go to Results (selected record)	`CTRL` + `SHIFT` +
Go to Detail (selected tab)	`CTRL` + `SHIFT` +
Go to Next page	`CTRL` +
Go to Previous page	`CTRL` +

Go to Next record / image	/
Go to Previous record / image	/
Scroll Up	`Page Up`
Scroll Down	`Page Down`
Scroll to Top	`CTRL` + `Home`
Scroll to Bottom	`CTRL` + `End`

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

Save query

Query Tree

Refine Options

Full Query

Side-by-side view shortcuts

Analysis

Go to Next tab
Go to Previous tab